Vivos Therapeutics Replaces CFO with Outsourced Leader Amid Financial Distress
VVOS sits 17% above its 52-week low of $0.364 on light trading volume (0.1× avg).
Summary
Vivos Therapeutics replaced its CFO with an outsourced executive from The CFO Portal, granting significant equity awards to both the departing and incoming officers. The move comes amid a going-concern warning and Nasdaq delisting risk, with the new CFO tasked with leading capital-raising and listing-compliance efforts.
Key Events · Executive and Board Changes · VVOS
-
CFO Departure and Transition
Bradford Amman resigned as CFO on July 31, 2026, transitioning to a non-executive role for 90 days and then an advisory role for 180 days. His separation agreement includes 250,000 fully vested shares and options for 150,000 shares.
-
Outsourced CFO Appointment
Roman Franklin of The CFO Portal, LLC was appointed CFO and Principal Financial Officer. The company will pay a $27,000 monthly retainer and grant Franklin a 552,000-share stock option, with an annual equity award valued at approximately $237,360.
-
Equity Dilution Risk
The combined equity grants to the departing and incoming CFOs total 952,000 shares (including options), representing significant potential dilution for a company with only about 13.7 million shares outstanding.
-
Financial Distress Context
The CFO change follows a Q1 2026 net loss of $7.8 million, a going-concern warning, and recent debt restructuring. The new CFO's mandate includes Nasdaq continued-listing remediation and capital-raising support.
Analysis · VVOS · Industrial Applications And Services
Vivos Therapeutics, a micro-cap medical device company with a going-concern warning and a stock price near $0.43, has replaced its CFO with an outsourced executive from The CFO Portal. The outgoing CFO, Bradford Amman, will receive 250,000 fully vested shares and options for 150,000 shares as part of his separation — a significant equity grant for a company with a market cap of only $5.8 million. The new CFO, Roman Franklin, will be compensated through a $27,000 monthly retainer and a 552,000-share option grant, with an annual equity award valued at roughly $237,000. The transition comes just weeks after the company restructured debt and announced a rights offering, and the new CFO's mandate explicitly includes Nasdaq continued-listing remediation and capital-raising support. The equity grants to both the departing and incoming CFOs represent a material dilution risk for existing shareholders, and the reliance on an outsourced CFO underscores the company's fragile financial position.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 29.4% of the 1495 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.39%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VVOS was trading at $0.43 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $5.8M. The 52-week trading range was $0.36 to $5.69. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.